Literature DB >> 11033281

Long-term follow-up of vitamin B(6)-responsive West syndrome.

Y Ohtsuka1, T Ogino, T Asano, J Hattori, H Ohta, E Oka.   

Abstract

We performed a clinical and electroencephalographic follow-up study on 25 patients with West syndrome that was responsive to vitamin B(6) (eight cryptogenic patients and 17 symptomatic patients) who were older than 3 years at the last follow-up. All cryptogenic patients and 13 symptomatic patients were seizure free at the last follow-up. All cryptogenic patients and seven symptomatic patients had intelligent quotient or developmental quotient scores of 75 or higher. The recurrence of clinical seizures was always associated with increases in epileptic discharges. We could successfully discontinue pyridoxal phosphate administration in four cryptogenic and four symptomatic patients who were 1 year, 8 months to 24 years old.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033281     DOI: 10.1016/s0887-8994(00)00185-5

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  4 in total

1.  Clinical characteristics of two cohorts of infantile spasms: response to pyridoxine or topiramate monotherapy.

Authors:  Jiao Xue; Ping Qian; Hui Li; Ye Wu; Hui Xiong; Yue-Hua Zhang; Zhi-Xian Yang
Journal:  World J Pediatr       Date:  2018-04-26       Impact factor: 2.764

Review 2.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

3.  Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy.

Authors:  H-S Wang; M-F Kuo; M-L Chou; P-C Hung; K-L Lin; M-Y Hsieh; M-Y Chang
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

4.  The Clinical Features and Long-Term Follow-Up of Vitamin B6-Responsive Infantile Spasms in a Chinese Cohort.

Authors:  Xianru Jiao; Pan Gong; Yue Niu; Zhao Xu; Ye Wu; Yuehua Zhang; Zhixian Yang
Journal:  Front Neurol       Date:  2022-05-12       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.